Vanda Pharmaceuticals Inc (VNDA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Vanda Pharmaceuticals Inc (VNDA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9809
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Vanda Pharmaceuticals Inc (Vanda Pharmaceuticals) is a specialty pharmaceutical company that develops and commercializesnovel therapies for the treatment of central nervous system disorders. The company’s products include Hetlioz, a melatonin receptor agonist for the treatment of non-24-hour sleep-wake disorder; and Fanapt, an atypical antipsychotic for the treatment of schizophrenia in adults. Its pipeline portfolio includes Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist for pruritus in atopic dermatitis; VQW-765 (formerly AQW-051), an alpha-7 nicotinic acetylcholine receptor for CNS disorders; and VTR-297 (formerly Trichostatin A) for oncology indications. Vanda Pharmaceuticals is headquartered in Washington DC, the US.

Vanda Pharmaceuticals Inc (VNDA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Vanda Pharma Enters into Licensing Agreement with UC San Francisco 10
Novartis Pharma Enters into Licensing Agreement with Vanda Pharma for AQW-051 11
Vanda Pharma Enters Into Licensing Agreement With Eli Lilly For VLY-686 12
Equity Offering 13
Vanda Pharma Prices Public Offering of Shares for USD93.5 Million 13
Vanda Pharma Raises USD25 Million in Private Placement of Common Stock 15
Vanda Pharma Raises USD66.7 Million in Public Offering of Shares 17
Vanda Pharma Completes Public Offering Of Shares For US$52 Million 19
Acquisition 21
Vanda Pharma May Sell Itself 21
Vanda Pharmaceuticals Inc – Key Competitors 22
Vanda Pharmaceuticals Inc – Key Employees 23
Vanda Pharmaceuticals Inc – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Nov 07, 2018: Vanda Pharmaceuticals reports third quarter 2018 financial results 25
Aug 01, 2018: Vanda pharmaceuticals reports second quarter 2018 financial results 26
May 02, 2018: Vanda Pharmaceuticals Reports First Quarter 2018 Financial Results 27
Feb 14, 2018: Vanda Pharmaceuticals Reports Fourth Quarter 2017 Financial Results 28
Jan 07, 2018: Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2017 Revenue Results and 2018 Guidance 29
Nov 07, 2017: Vanda Pharmaceuticals Reports Third Quarter 2017 Financial Results 30
Aug 02, 2017: Vanda Pharmaceuticals Reports Second Quarter 2017 Financial Results 31
May 02, 2017: Vanda Pharmaceuticals Reports First Quarter 2017 Financial Results 32
Feb 15, 2017: Vanda Pharmaceuticals Reports Fourth Quarter 2016 and Full Year 2016 Financial Results 33
Jan 09, 2017: Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2016 Revenue Results and 2017 Financial Guidance 34
Legal and Regulatory 35
Nov 01, 2018: Vanda receives FDA letter regarding corporate webpage 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vanda Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Vanda Pharma Enters into Licensing Agreement with UC San Francisco 10
Novartis Pharma Enters into Licensing Agreement with Vanda Pharma for AQW-051 11
Vanda Pharma Enters Into Licensing Agreement With Eli Lilly For VLY-686 12
Vanda Pharma Prices Public Offering of Shares for USD93.5 Million 13
Vanda Pharma Raises USD25 Million in Private Placement of Common Stock 15
Vanda Pharma Raises USD66.7 Million in Public Offering of Shares 17
Vanda Pharma Completes Public Offering Of Shares For US$52 Million 19
Vanda Pharma May Sell Itself 21
Vanda Pharmaceuticals Inc, Key Competitors 22
Vanda Pharmaceuticals Inc, Key Employees 23
Vanda Pharmaceuticals Inc, Subsidiaries 24

List of Figures
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Vanda Pharmaceuticals Inc (VNDA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Endo International Plc (ENDP):企業の財務・戦略的SWOT分析
    Endo International Plc (ENDP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Varian Medical Systems, Inc.:企業のM&A・事業提携・投資動向
    Varian Medical Systems, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Varian Medical Systems, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • ifa systems AG (IS8):企業の財務・戦略的SWOT分析
    ifa systems AG (IS8) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Genera Biosystems Ltd (GBI)-製薬・医療分野:企業M&A・提携分析
    Summary Genera Biosystems Ltd (GBL) is a developer and commercializer of multiplexed molecular diagnostic testing products. The company offers RTIplex and PapType molecular diagnostic test. Its RTIplex is a multiplexed and automated PCR based test for detection of viral and bacterial respiratory pat …
  • The Boston Consulting Group:企業の戦略・SWOT・財務情報
    The Boston Consulting Group - Strategy, SWOT and Corporate Finance Report Summary The Boston Consulting Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Humanigen Inc (HGEN)-製薬・医療分野:企業M&A・提携分析
    Summary Humanigen Inc(Humanigen) formerly known as KaloBios Pharmaceuticals Inc, is a development stage biopharmaceutical company that develops medicines for neglected and rare diseases. The company offers benznidazole, a nitroimidazole derivative used for the treatment of Chagas disease, a parasiti …
  • Shimano Inc. (7309):企業の財務・戦略的SWOT分析
    Shimano Inc. (7309) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Blue Apron Inc. (APRN):企業の財務・戦略的SWOT分析
    Blue Apron Inc. (APRN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • AccentCare Inc:企業の戦略的SWOT分析
    AccentCare Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • InVitae Corp (NVTA):製薬・医療:M&Aディール及び事業提携情報
    Summary Invitae Corp (Invitae), formerly Locus Development Inc, is a genetic information company which processes DNA-containing samples, analyzes information about patient-specific genetic variation and generates test reports for clinicians and their patients. The company’s portfolio of diagnostic t …
  • SAS Group:企業のM&A・事業提携・投資動向
    SAS Group - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's SAS Group Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Marksmen Energy Inc (MAH):企業の財務・戦略的SWOT分析
    Summary Marksmen Energy Inc (Marksmen Energy), formerly Marksmen Resources Ltd, is an oil and gas exploration and development company that explores and develops light oil assets in Ohio. The company acquires, explores, operates, manages, produces and develops oil and gas properties in Western Canada …
  • Intercept Energy Services Inc (IES):石油・ガス:M&Aディール及び事業提携情報
    Summary Intercept Energy Services Inc (Intercept Energy), formerly Global Green Matrix Corp is an oilfield service firm that offers water heating services. The firm provides services such as oilfield services, energy extraction and related services, frac water heating, oil sands processing, and oilf …
  • DHL Supply Chain:企業の戦略・SWOT・財務分析
    DHL Supply Chain - Strategy, SWOT and Corporate Finance Report Summary DHL Supply Chain - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • iCAD Inc (ICAD):企業の財務・戦略的SWOT分析
    iCAD Inc (ICAD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Courtagen Life Sciences Inc-医療機器分野:企業M&A・提携分析
    Summary Courtagen Life Sciences Inc (Courtagen) is a medical device company that provides neurological treatment solutions. The company’s products include neuro-development panels, lysosomal disorder panels, syndrome panels, comprehensive epilepsy panels, focus epilepsy panels, metabolism test equip …
  • Korea Gas Corp (036460)-石油・ガス分野:企業M&A・提携分析
    Summary Korea Gas Corp (KOGAS) is a vertically integrated natural gas company active in upstream midstream and downstream segments of natural gas industry. It explores, produces and distributes natural gas. The company also purifies and sells by-products; imports and exports natural gas and liquefie …
  • Swelect Energy Systems Ltd (SWELECTES):電力:M&Aディール及び事業提携情報
    Summary Swelect Energy Systems Ltd (SESL), formerly Numeric Power Systems Ltd is an energy company that manufactures and markets renewable energy products and iron and steel products. The company’s renewable energy products include solar pv modules, solar inverter, solar water pump and energy effici …
  • LCI Industries:企業の戦略・SWOT・財務分析
    LCI Industries - Strategy, SWOT and Corporate Finance Report Summary LCI Industries - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Dover Corporation:企業の戦略・SWOT・財務分析
    Dover Corporation - Strategy, SWOT and Corporate Finance Report Summary Dover Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆